{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T06:07:46Z","timestamp":1771308466080,"version":"3.50.1"},"reference-count":33,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2021YFF 1201104"],"award-info":[{"award-number":["2021YFF 1201104"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173156"],"award-info":[{"award-number":["82173156"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Hospitals Authority Clinical Medicine Development of Special Funding","award":["ZYLX202116"],"award-info":[{"award-number":["ZYLX202116"]}]},{"name":"Science Foundation of Peking University Cancer Hospital","award":["PY202317"],"award-info":[{"award-number":["PY202317"]}]},{"name":"Capital Research and Translational Application of Clinical Characteristic Diagnosis and Treatment","award":["Z221100007422030"],"award-info":[{"award-number":["Z221100007422030"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The prognostic value of conventional high-risk factors and the benefits of adjuvant chemotherapy (ACT) in stage II colon cancer with deficient mismatch repair (dMMR) remain controversial. The function of ACT in stage II dMMR colon cancer and survival results were assessed in this research. Methods: 273 patients with stage II dMMR colon cancer who had curative resection between August 2010 and October 2023 underwent a retrospective analysis. Clinicopathologic variables, postoperative treatment strategies, and survival endpoints were systematically assessed. Independent prognostic factors were identified using a multivariable Cox proportional hazards regression model. For subgroup analyses, a propensity score\u2013matched (PSM) approach was used to minimize intergroup imbalances. Overall survival (OS) and disease-free survival (DFS) were evaluated using the Kaplan\u2013Meier approach. Results: 177 (64.8%) patients had at least one high-risk factor. With a median follow-up of 62.6 months, the estimated 5-year OS and DFS rates were 94.7% and 89.8%. Age \u2265 65 years and examination of fewer than 12 lymph nodes were independently associated with OS. For DFS, age \u2265 65 years, LNs &lt; 12, and receipt of ACT were identified as independent prognostic factors. According to subgroup analyses, ACT was linked to better OS and DFS in patients with high-risk features or poorly differentiated histology. Results were similar after propensity score matching. Conclusion: Traditional high-risk features also exert prognostic impact on this population. ACT appeared to be associated with improved survival in selected high-risk patients, particularly those with poorly differentiated histology.<\/jats:p>","DOI":"10.3390\/cancers18040629","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T14:09:54Z","timestamp":1771250994000},"page":"629","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selective Benefit of Adjuvant Chemotherapy in Stage II dMMR Colon Cancer with High-Risk Features or Poorly Differentiated Histology: A Retrospective Study"],"prefix":"10.3390","volume":"18","author":[{"given":"Yonglin","family":"Huang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuye","family":"Gao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjie","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingyu","family":"Xie","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junpeng","family":"Pei","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfeng","family":"Yao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiancheng","family":"Zhan","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahua","family":"Leng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiwen","family":"Wu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","article-title":"Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers","volume":"22","author":"Ambrosini","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","first-page":"e240029","article-title":"Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Benson","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","article-title":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial","volume":"28","author":"Roth","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","article-title":"Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer","volume":"28","author":"Sargent","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Liao, L., Tang, J., Hong, Z., Jiang, W., Li, Y., Kong, L., Han, K., Hou, Z., Zhang, C., and Zhou, C. (2024). The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: A retrospective study. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-11821-w"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/aje\/kwy049","article-title":"Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses","volume":"187","author":"Wang","year":"2018","journal-title":"Am. J. Epidemiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"153288","DOI":"10.1016\/j.prp.2020.153288","article-title":"Clinicopathological features of mismatch repair protein expression patterns in colorectal cancer","volume":"217","author":"Lee","year":"2021","journal-title":"Pathol. Res. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Tabernero","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12957-020-01863-2","article-title":"A reappraisal of lymph node dissection in colorectal cancer during primary surgical resection","volume":"18","author":"Chen","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1245\/s10434-025-18285-7","article-title":"Adjuvant Chemotherapy and Survival in MSI-High Stages II and III Colon Cancer: Impact of Histopathologic Risk Stratification","volume":"32","author":"Erkaya","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.12659\/MSM.918133","article-title":"Prognostic Value of Lymphovascular Invasion in Patients with Stage III Colorectal Cancer: A Retrospective Study","volume":"25","author":"Zhong","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijsu.2016.08.528","article-title":"Lymphovascular and perineural invasion are associated with poor prognostic features and outcomes in colorectal cancer: A retrospective cohort study","volume":"37","author":"Attwood","year":"2017","journal-title":"Int. J. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4132\/jptm.2015.02.05","article-title":"Pathologic Factors Associated with Prognosis after Adjuvant Chemotherapy in Stage II\/III Microsatellite-Unstable Colorectal Cancers","volume":"49","author":"Kim","year":"2015","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ejso.2022.06.024","article-title":"Mucinous histology is associated with poor prognosis in locally advanced colorectal adenocarcinoma treated with postoperative first-line adjuvant chemotherapy: A systematic review and meta-analysis","volume":"48","author":"Zhang","year":"2022","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zhu, L., Ling, C., Xu, T., Zhang, J., Zhang, Y., Liu, Y., Fang, C., Yang, L., Zhuang, W., and Wang, R. (2021). Clinicopathological Features and Survival of Signet-Ring Cell Carcinoma and Mucinous Adenocarcinoma of Right Colon, Left Colon, and Rectum. Pathol. Oncol. Res., 27.","DOI":"10.3389\/pore.2021.1609800"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lan, Y.T., Chang, S.C., Lin, P.C., Lin, C.C., Lin, H.H., Huang, S.C., Lin, C.H., Liang, W.Y., Chen, W.S., and Jiang, J.K. (2021). Clinicopathological and Molecular Features of Colorectal Cancer Patients With Mucinous and Non-Mucinous Adenocarcinoma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.620146"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/jso.27175","article-title":"Peritoneal recurrence after resection for Stage I\u2013III colorectal cancer: A population analysis","volume":"127","author":"Aiken","year":"2023","journal-title":"J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1200\/JCO.24.00394","article-title":"Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis","volume":"42","author":"Chibaudel","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"djv438","DOI":"10.1093\/jnci\/djv438","article-title":"Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study","volume":"108","author":"Tougeron","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","article-title":"Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study","volume":"33","author":"Vernerey","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.21873\/invivo.11523","article-title":"Clinical Implications of Mismatch Repair Status in Patients With High-risk Stage II Colon Cancer","volume":"33","author":"Baek","year":"2019","journal-title":"Vivo"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41379-020-0634-9","article-title":"Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II\u2013III colon cancer","volume":"34","author":"Hestetun","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13000-024-01571-5","article-title":"Concordance between immunohistochemistry and MSI analysis for detection of MMR\/MSI status in colorectal cancer patients","volume":"19","author":"Faizee","year":"2024","journal-title":"Diagn. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1470-2045(20)30685-9","article-title":"Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): A randomised, controlled, phase 3, superiority trial","volume":"22","author":"Xu","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1470-2045(14)71168-4","article-title":"Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: A retrospective, population-based study","volume":"16","author":"Bertelsen","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1200\/JCO.21.02538","article-title":"Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update","volume":"40","author":"Baxter","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.2012.42.5645","article-title":"Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial","volume":"30","author":"Tournigand","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1200\/JCO.2010.30.1366","article-title":"Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer","volume":"29","author":"Hutchins","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.1158\/1078-0432.CCR-12-0605","article-title":"Mutation profiling and microsatellite instability in stage II and III colon cancer: An assessment of their prognostic and oxaliplatin predictive value","volume":"18","author":"Gavin","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/DCR.0000000000003845","article-title":"Surgical Outcomes in Metastatic Mismatch Repair-Deficient\/Microsatellite Instability-High Colorectal Cancer After Disease Control With Immune Checkpoint Inhibitors: A Retrospective Observational Study","volume":"68","author":"Sui","year":"2025","journal-title":"Dis. Colon. Rectum"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"32-32","DOI":"10.1200\/GO.2023.9.Supplement_1.32","article-title":"Postoperative circulating tumor DNA-based molecular residual disease in patients with BRAF V600E and MSI-H colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan","volume":"9","author":"Watanabe","year":"2023","journal-title":"JCO Glob. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/629\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:18:42Z","timestamp":1771305522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18040629"],"URL":"https:\/\/doi.org\/10.3390\/cancers18040629","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]}}}